Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
- PMID: 29606112
- PMCID: PMC5879744
- DOI: 10.1186/s12889-018-5371-3
Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is resistant to the two main first-line anti-tuberculosis drugs: rifampicin and isoniazid. It is a major threat to public health worldwide. The objective of this study was to assess the potential risk factors for multidrug-resistant tuberculosis among patients undergoing MDR-TB treatment at two community hospitals in Ethiopia.
Methods: A case-control study design was conducted from February 1, 2016, to April 29, 2016. TB-positive patients with MDR-TB and non-MDR-TB were considered as cases and controls, respectively. A total of 219 study participants were included in the study. An interviewer-administered structured questionnaire was used to collect primary data from the patients, and a checklist was used to collect data from the clinical records. Bivariate and multivariate logistic regression analyses were used to assess the potential risk factors for the occurrence of MDR-TB.
Results: The odds of developing MDR-TB were higher in patients previously treated with anti-TB drugs (odds ratio [OR] = 6.1, 95%CI: 2.92-12.62, P < 0.001), those with a history of contact with known TB patients (OR = 2.1, 95%CI: 1.04-4.43, P < 0.001), those living in a rural setting (OR = 5.6, 95%CI: 2.14-14.46, P = 0.001), those with a history of alcohol consumption (OR = 4.3, 95%CI: 2.29-10.49, P < 0.001) and those without a job (OR = 2.4, 95%CI: 1.06-5.42, P = 0.001).
Conclusions: The study revealed that contact with known TB patients, previous TB treatment, residence area, lack of a job, and alcohol consumption were potential risk factors for the occurrence of MDR-TB. Enhancing public health education, intensifying directly observed therapy programmes for all TB patients and designing control strategies are recommended.
Keywords: Anti-TB drugs; MDR-TB; Risk factors; TB.
Conflict of interest statement
Ethics approval and consent to participate
This study was approved by the Oromia Health Bureau (Ref no. BEEFO/1–8/1239). A statement about the purpose of the study was read and explained to each study participant. Only those who gave verbal consent to participate in the study were included in the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
-
- World health organization . Global Tuberculosis report. Geneva: World health organization; 2015.
-
- European center for disease control . Tuberculosis surveillance and monitoring in Europe. Surveillance report. Stockholm: European center for disease control; 2016.
-
- World health organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. The end TB strategy. 2014. - PubMed
-
- World health organization . World Health Organization: global tuberculosis control. Geneva: World health organization; 2013.
-
- Federal Ministry of Health . Guideline for program and clinical management of drug resistant tuberculosis. 2009.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
